Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Arguably the prototype of "getting it right," deucravacitinib (Sotyktu) hits the regulatory domain of TYK2, locking the ...

ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, ...

Deucravacitinib, a tyrosine kinase 2 inhibitor, significantly improves quality of life in patients with scalp psoriasis compared to placebo. Patients on deucravacitinib showed greater improvements ...

Please provide your email address to receive an email when new articles are posted on . Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s ...

Deucravacitinib (Sotyktu) demonstrated efficacy in treating patients with active psoriatic arthritis (PsA), achieving higher American College of Rheumatology (ACR) 20 response rates (ie ...

BMS isn't letting the setback dampen its enthusiasm for deucravacitinib, saying that it remains committed to developing it for IBD, and stands by its peak sales forecast for the drug of $4 billion ...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start their ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Improved targeting of the molecular drivers of psoriasis has ...